Beam Therapeutics Appoints Carole Ho, M.D., to Board of Directors
Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
We are seeking an energetic scientist with broad experience in the development of analytical separation methods including but not limitedRead More
We are seeking an energetic individual with broad experience in the development and validation of analytical and biophysical assays forRead More
The successful candidate will assist in the development and execution of immunoassays within the Analytical Development team supporting Pharmaceutical SciencesRead More
26 Landsdowne Street
Cambridge, MA 02139